Detection of lymphoma in bone marrow by whole-body positron emission tomography.

Positron emission tomography (PET) is a whole-body imaging technique using 18 fluorine-fluorodeoxyglucose (FDG), whose uptake is increased in tumor cells. Published studies have shown PET to be an effective method of staging lymphoma and to be more sensitive than CT at detecting extranodal disease. The purpose of this study was to determine whether the increased marrow uptake of FDG observed in some lymphoma patients during routine staging PET scans represented marrow involvement by disease. PET scans of 50 patients with Hodgkin's (12) and non-Hodgkin's (38) lymphoma were analyzed by three independent observers and the marrow graded as normal or abnormal using a visual grading system. Unilateral iliac crest marrow aspirates and biopsies were performed on all patients. The PET scan and marrow histology agreed in 39 patients (78%), being concordant positive in 13 and concordant negative in 26 patients. In 8 patients the PET scan showed increased FDG uptake but staging biopsy was negative; in 4 of these 8 patients the PET scan showed a normal marrow background with focal FDG "hot spots" distant from the site biopsied. In 3 patients the marrow biopsy specimen was positive but the PET scan normal; 2 of these 3 patients had non-Hodgkin's lymphoma whose malignant cells did not take up FDG at lymph node or marrow disease sites. Therefore, there were only 5 patients (10%) in whom there was a difference between the PET scan and biopsy result which could not be fully explained. Visual interpretation of marrow FDG uptake during whole-body staging PET scans can correctly assess marrow disease status in a high proportion of lymphoma patients. PET has the potential to reduce the need for staging marrow biopsy.

[1]  S. Gregory,et al.  Bilateral trephine bone marrow biopsy for staging non-Hodgkin's lymphoma--a second look. , 1989, Hematologic pathology.

[2]  D. Weisenburger,et al.  Mantle cell lymphoma-- an entity comes of age. , 1996, Blood.

[3]  C. Fegan,et al.  Mantle cell leukaemia? , 1996, British journal of haematology.

[4]  M. Kaminski,et al.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.

[5]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[6]  R. Musumeci,et al.  New imaging techniques in staging lymphomas , 1994, Current opinion in oncology.

[7]  S. Minoshima,et al.  The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  D. Lee,et al.  Bone marrow scintigraphy using technetium-99m-antigranulocyte antibody in hematologic disorders. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  M E Phelps,et al.  Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  C. Bloomfield,et al.  Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. , 1975, Annals of internal medicine.

[11]  O. Warburg On the origin of cancer cells. , 1956, Science.

[12]  Elaine S. Jaffe,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[13]  K. Någren,et al.  Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  V. Diehl,et al.  Malignant lymphoma: bone marrow imaging versus biopsy. , 1989, Radiology.

[15]  J H Thrall,et al.  Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. , 1993, Radiographics : a review publication of the Radiological Society of North America, Inc.

[16]  R. Wahl Targeting glucose transporters for tumor imaging: "sweet" idea, "sour" result. , 1979, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  B F Hutton,et al.  Simultaneous emission and transmission measurements for attenuation correction in whole-body PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  I. Magrath,et al.  Bone marrow involvement in young patients with non-Hodgkin's lymphoma: the importance of multiple bone marrow samples for accurate staging. , 2006, Medical and pediatric oncology.

[19]  R. Castellino,et al.  Non-Hodgkin lymphoma: influence of lymphography, CT, and bone marrow biopsy on staging and management. , 1989, Radiology.

[20]  J. Itami,et al.  Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  H. Minn,et al.  Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. , 1995, Blood.

[22]  M. Wolf,et al.  Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma. , 1990, Journal of clinical pathology.

[23]  B. Glimelius,et al.  Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  M. Phelps,et al.  Positron emission tomography scanning in cancer. , 1994, Cancer investigation.

[25]  S. Barrington,et al.  Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning. , 1995, Clinical oncology (Royal College of Radiologists (Great Britain)).

[26]  R Paul,et al.  Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  S. Reske,et al.  Bone marrow immunoscintigraphy compared with conventional bone scintigraphy for the detection of bone metastases. , 1993, Acta oncologica.

[28]  E. Macintyre,et al.  The value of staging bone marrow trephine biopsy in Hodgkin's Disease , 1987, European journal of haematology.

[29]  A. Shields,et al.  Comparison of initial lymphoma staging using computed tomography (CT) and magnetic resonance (MR) imaging , 1994, American journal of hematology.

[30]  T. Fukumura,et al.  Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.